{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:00:03Z","timestamp":1784300403480,"version":"3.55.0"},"reference-count":48,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Urine drug testing (UDT) is an important analytical\/bio\u2010analytical technique that has inevitably become an integral and vital part of a testing programme for diagnostic purposes. This manuscript presents a tailor\u2010made LC\u2010MS\/MS quantitative assay method development and validation for a custom group of 33 pain panel drugs and their metabolites belonging to different classes (opiates, opioids, benzodiazepines, illicit, amphetamines, etc.) that are prescribed in pain management and depressant therapies. The LC\u2010MS\/MS method incorporates two experiments to enhance the sensitivity of the assay and has a run time of about 7\u00a0minutes with no prior purification of the samples required and a flow rate of 0.7\u00a0mL\/min. The method also includes the second\u2010stage metabolites for some drugs that belong to different classes but have first\u2010stage similar metabolic pathways that will enable to correctly identify the right drug or to flag the drug that might be due to specimen tampering. Some real case examples and difficulties in peak picking were provided with some of the analytes in subject samples. Finally, the method was deliberated with some randomly selected de\u2010identified clinical subject samples, and the data evaluated from \u201cdirect dilute and shoot analysis\u201d and after \u201cglucuronide hydrolysis\u201d were compared. This method is now used to run routinely more than 100 clinical subject samples on a daily basis.<\/jats:p>","DOI":"10.1111\/bcpt.13519","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T03:04:38Z","timestamp":1604286278000},"page":"533-550","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["LC\u2010MS\u2010sMRM method development and validation of different classes of pain panel drugs and analysis of clinical urine samples"],"prefix":"10.1111","volume":"127","author":[{"given":"M. Athar","family":"Masood","sequence":"first","affiliation":[{"name":"Laboratory of Proteomics and Analytical Technologies Advanced Technology Program SAIC\u2010Frederick, Inc. Frederick National Laboratory for Cancer Research Frederick Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Veenstra","sequence":"additional","affiliation":[{"name":"Laboratory of Proteomics and Analytical Technologies Advanced Technology Program SAIC\u2010Frederick, Inc. Frederick National Laboratory for Cancer Research Frederick Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-2670(03)00889-4"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60750-7"},{"key":"e_1_2_6_4_1","volume-title":"Cancer Pain Relief: With a guide to opioid availability","author":"World Health Organization","year":"1996"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-8981(01)00714-8"},{"key":"e_1_2_6_6_1","unstructured":"https:\/\/www.cdc.gov\/drugoverdose\/epidemic. Accessed October 26 2020."},{"key":"e_1_2_6_7_1","first-page":"635","article-title":"Urine drug screening: a valuable office procedure","volume":"81","author":"Standridge JB","year":"2010","journal-title":"Am Fam Physician"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.36076\/ppj.2010\/13\/E1","article-title":"Protocol for accuracy of point of care (POC) or in\u2010office drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography t\u00e1ndem mass spectrometry (LC\/MS\/MS)","volume":"13","author":"Manchikanti L","year":"2010","journal-title":"Pain Physician"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm.2011.739"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2010.08.008"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2010.05.046"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2011.11.044"},{"key":"e_1_2_6_13_1","unstructured":"US Department of Health and Human Services Food and Drug Administration (FDA) Center for drug evaluation and research (cder) guidance for industry bioanalytical method validation.https:\/\/www.fda.gov\/media\/70858\/download. Accessed October 22 2020."},{"key":"e_1_2_6_14_1","unstructured":"Clinical and Laboratory Standards Institute (CLSI) Liquid chromatography mass spectrometry methods: Approved guidelines CLSI\u2010C62A Oct. 2014.Mass spectrometry in the clinical laboratory: General principles and guidance approved guidance CLSI\u2010C50\u2010A 2007."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2006.11.008"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2012.01350.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.4065\/83.1.66"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200312000-00011"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/245415"},{"key":"e_1_2_6_20_1","first-page":"452","article-title":"Bioanalytical method validation, May 2001; Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices for method validation in forensic toxicology, guidance to authors","volume":"37","author":"FDA Guidance for Industry","year":"2013","journal-title":"J Anal Toxicol"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2010.08.008"},{"key":"e_1_2_6_22_1","volume-title":"Forensic Toxicology Laboratory Guidelines","year":"2002"},{"key":"e_1_2_6_23_1","volume-title":"Laboratory Accreditional Requirements and Operating Standards","year":"2002"},{"key":"e_1_2_6_24_1","unstructured":"https:\/\/www.cms.gov\/Regulations\u2010and\u2010Guidance\/Legislation\/CLIA\/Proficiency_Testing_Providers. Accessed October 10 2020."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2005.01.014"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595230410001704208"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkv024"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.028878"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2007.03.008"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkr024"},{"key":"e_1_2_6_31_1","first-page":"273","article-title":"An evaluation of the diagnostic accuracy of liquid chromatography\u2010tandem mass spectrometry versus immunoassay drug testing in pain patients","volume":"13","author":"Pesce A","year":"2010","journal-title":"Pain Phys"},{"key":"e_1_2_6_32_1","volume-title":"Disposition of toxic drugs and chemicals in man","author":"Baselt RC","year":"2011"},{"key":"e_1_2_6_33_1","volume-title":"Fundamentals of biochemical pharmacology","author":"Bacq ZM","year":"1975"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bku002"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-012-0274-7"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bks020"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.12.005"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2003.07.008"},{"key":"e_1_2_6_39_1","first-page":"1","article-title":"Evaluation of high\u2010resolution mass spectrometry for urine toxicology screening in a pain management setting","volume":"00","author":"Crews BO","year":"2012","journal-title":"J Anal Toxicol"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2009.138602"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9872.1000135"},{"key":"e_1_2_6_42_1","first-page":"1","article-title":"Analytical considerations when monitoring pain medications by LC\u2010MS\/ MS","volume":"5","author":"Pesce A","year":"2012","journal-title":"J Anal Bioanal Tech"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/anatox\/35.1.32"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/30.8.570"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/31.7.419"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.2945"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bks063"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2009.07.019"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/31.1.1"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.13519","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T07:06:25Z","timestamp":1693638385000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":48,"aliases":["10.1111\/bcpt.12877"],"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/bcpt.13519"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13519","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"2017-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}